Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Asmakast vs Singulair in Healthy Volunteers
NCT02480049Phase 1Completed
- Sponsor
- Genuine Research Center
- Start
- Aug 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of montelukast in asthma and allergic rhinitis (AR) (2 arms), sponsored by Genuine Research Center. Primary endpoints: Maximal measured plasma concentration at 24 hours, Area Under the plasma concentration-time curve from time zero to t at 24 hours and 1 more. Started Aug 2014; status: completed.
02
Drugs
montelukast
03
Conditions
asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02480049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02480049.